Skip to main content

Advertisement

SpringerLink
Log in

Nature Biotechnology’s academic spinouts 2022

  • News Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Nature Biotechnology’s annual survey highlights academic start ups that are, among other things, correcting misfolded or disordered proteins, creating second-generation GPCR agonists, building a new gene delivery platform and mining cancer genomes for novel targets.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Author information

Authors and Affiliations

  1. Philadelphia, PA, USA

    Michael Eisenstein

  2. Portland, ME, USA

    Charles Schmidt

  3. Pasadena, CA, USA

    Laura DeFrancesco

Authors
  1. Michael Eisenstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Laura DeFrancesco
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eisenstein, M., Schmidt, C. & DeFrancesco, L. Nature Biotechnology’s academic spinouts 2022. Nat Biotechnol 41, 1669–1678 (2023). https://doi.org/10.1038/s41587-023-02023-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-023-02023-z

  • Springer Nature America, Inc.

Search

Navigation